A new era in the fight against measles and rubella

抗击麻疹和风疹的新时代

The Measles Initiative was formed in 2001 to establish a global partnership to coordinate efforts to prevent child deaths and morbidity caused by the highly contagious measles virus. In 2012, the founding partners -- American Red Cross, U.S. Centers for Disease Control and Prevention, the United Nations Foundation, UNICEF and the World Health Organization (WHO) – agreed to include rubella elimination under a new name, the Measles and Rubella Initiative (M&RI).

麻疹倡议成立于2001年，目的是建立全球伙伴关系，共同协调努力，以预防因高传染性麻疹病毒造成的儿童死亡和发病。2012年，各创始成员——美国红十字会、美国疾病控制和预防中心、联合国基金会、联合国儿童基金会和世界卫生组织——同意将消除风疹纳入一个新名称，即麻疹和风疹倡议（M&RI）。

Huge strides have been made since then. The Initiative has helped deliver measles vaccines to children worldwide, contributing to saving over 56 million lives globally since its formation and invested more than US$1.2 billion in measles and rubella control activities, in partnership with Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation (BMGF).

自那时起，已经取得了巨大的进步。该倡议自成立以来，帮助向世界各地的儿童提供了麻疹疫苗，拯救了全球超过5600万人的生命，并与全球疫苗和免疫联盟、疫苗联盟和比尔及梅琳达·盖茨基金会（BMGF）合作，在麻疹和风疹控制活动中投资了超过12亿美元。

The impact of these investments is significant. From 2000 to 2021, the annual number of estimated measles deaths decreased 83 per cent, from 761 000 to 128 000. While much progress has been made, the goal is to collaborate with countries and partners to achieve the Immunization Agenda 2030 (IA2030) target to save another 50 million lives through access to essential vaccines by the end of 2030, with measles immunization contributing a large percentage.

这些投资所造成的影响是巨大的。从2000年到2021年，每年预计麻疹死亡人数减少了83%，从761,000人减少到128,000人。虽然已经取得了很大进展，但其目标是与各国及合作伙伴合作，实现2030年免疫议程的目标，即到2030年底通过获得基本疫苗再拯救5000万人的生命，其中麻疹免疫占很大比例。

Towards that end, all founding partners adopted the Measles and Rubella Strategic Framework 2030, which is fully aligned with IA2030, an ambitious global strategy to maximize the lifesaving impact of vaccines.

为此，所有创始伙伴都通过了《2030年麻疹和风疹战略框架》，该框架与《2030年麻疹和风疹战略框架》完全一致，后者是一项雄心勃勃的全球战略，旨在最大限度地发挥疫苗拯救生命的影响。

M&RI then began a consultative process to fully integrate the strategy, coordination and action with IA2030 strategy and partnership processes. As a result of that process, the newly revitalized M&RI partnership will now be called the IA2030 Measles & Rubella Partnership (M&RP). The transition began on 1 January 2023 and has now been formalized.

然后，M&RI开始了一个咨询过程，以将战略、协调和行动与IA 2030战略和伙伴关系过程完全整合。作为这一进程的结果，新兴的M&RI伙伴关系如今将被称为IA 2030麻疹和风疹伙伴关系（M&RP）。过渡于2023年1月1日开始，现已正式确定。

Building on years of previous work together, the membership of the IA2030 M&RP will include the original five founders and has expanded to include Gavi and BMGF as core partners.

在之前多年合作的基础上，IA 2030 M&RP的成员将包括最初的五位创始人，并已扩大到将Gavi和BMGF纳入核心合作伙伴之列。

The transition comes at a time when the world has seen the worst continued backsliding in global immunization coverage in 30 years, largely on account of the COVID-19 pandemic and related disruptions. It is opportune as we need to work more closely than ever before to address the nearly 40 per cent increase in the number of unvaccinated children globally.

这一转变发生在全球免疫覆盖率出现30年来最严重的持续下滑之际，其中的主要原因是受到新冠肺炎疫情和相关干扰。这是一个契机，因为我们需要比以往任何时候都更密切地合作，以解决全球未接种疫苗儿童人数增加近40%的问题。

IA2030 is in its early years, and we are among the first initiatives to transition to IA2030 management. We hope our success will serve as a precedent for other disease-specific initiatives in the coming years. This transitionis a step forward to overcome current challenges and ensure all children, everywhere, are protected against measles, rubella, and other vaccine-preventable diseases.

IA 2030正处于早期阶段，而我们是首批过渡到IA 2030管理计划中的一员。我们希望我们的成功将成为未来几年其他针对特定疾病的举措的先例。这一转变是克服当前挑战和确保世界各地所有儿童免受麻疹、风疹和其他疫苗可预防疾病的一个进步。

Sincerely,

真诚地，

American Red Cross

美国红十字会

Bill & Melinda Gates Foundation

比尔和梅琳达·盖茨基金会

Gavi, the Vaccine Alliance

疫苗联盟

US Centers for Disease Control

美国疾病控制中心

United Nations Foundation

联合国基金会

UNICEF

儿童基金会

WHO

世界卫生组织

About the Measles & Rubella Partnership (M&RP) and Immunization Agenda 2030 (IA2030)

关于麻疹和风疹伙伴关系(M&RP）和2030年免疫议程(IA2030）

The Measles & Rubella Partnership (M&RP), previously the Measles & Rubella Initiative, has been helping deliver measles and rubella vaccines since 2000 to children worldwide, contributing to saving over 56 million lives and substantially reducing birth defects due to congenital rubella infections. Despite this progress, measles continues to be one of the leading vaccine preventable killer of children, globally. Under the umbrella of Immunization Agenda 2030 (IA2030) and guided by the Measles and Rubella Strategic Framework 2030 (MRSF), M&RP’s current mission includes addressing decline in national vaccination coverage, hastening COVID-19 pandemic recovery and accelerating progress towards creating a world free of measles and rubella. The partnership consists of American Red Cross, Bill & Melinda Gates Foundation, Gavi, the Vaccine Alliance, US CDC, United Nations Foundation, UNICEF and WHO.

麻疹和风疹伙伴关系（M&RP），前身为麻疹和风疹倡议，自2000年以来一直在帮助世界各地的儿童，向他们提供麻疹和风疹疫苗，帮助挽救了5600多万人的生命，并大大减少了先天性风疹感染造成的出生缺陷。尽管取得了这一进展，麻疹仍然是全球儿童的主要可预防疫苗杀手之一。在2030年免疫议程（IA 2030）的框架下，并在2030年麻疹和风疹战略框架（MRSF）的指导下，M&RP目前的任务包括解决全国疫苗接种覆盖率下降的问题，加快新冠肺炎疫情的恢复，并加快建设一个没有麻疹和风疹的世界。该伙伴关系由美国红十字会、比尔及梅琳达·盖茨基金会、免疫联盟、疫苗联盟、美国疾病预防控制中心、联合国基金会、联合国儿童基金会和世界卫生组织组成。

M&RP is part of IA2030, an ambitious global strategy to maximize the lifesaving impact of vaccines – one of the most successful and cost-effective public health interventions of all time. IA2030 aims to avert over 50 million deaths by 2030 through access to essential vaccines and help build healthcare systems that can withstand the impact of pandemics and deliver rapid vaccination response.

M&RP是IA 2030的一部分，IA 2030是一项雄心勃勃的全球战略，旨在最大限度地发挥疫苗挽救生命的作用，是有史以来最成功和最具成本效益的公共卫生干预措施之一。IA 2030的目标是到2030年通过获得基本疫苗以避免5000多万人死亡，并帮助建立能够承受流行病影响并提供快速疫苗接种反应的医疗保健系统。

For more information about the Measles and Rubella Partnership, please visit the Measles and Rubella Partnership website

有关麻疹和风疹伙伴关系的更多信息，请访问麻疹和风疹伙伴关系网站